Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

neurodegenerative

- PMLiVE

Takeda and Zinfandel abandon Alzheimer’s drug

Pioglitazone failed to show therapeutic improvements in late-stage testing

- PMLiVE

Axovant joins ever-growing Alzheimer’s failure club

5-HT6 inhibitor Intepirdine followsin the footsteps of Lundbeck's idalopirdine

Biogen Idec building

Biogen says trial extension data keep Alzheimer’s drug on track

Releases updated results from the PRIME trial of anti-amyloid drug aducanumab

- PMLiVE

Alzheon says data backs potential of Alzheimer’s candidate

US biotech points to new analysis of phase III results for tramiprosate

- PMLiVE

Woodford investment pushes Dementia Discovery Fund to £100m

Fund aims to back 40 projects over its 15-year term

Online therapy for dementia carers to be studied

UK researchers will assess computerised Cognitive Behaviour Therapy

- PMLiVE

Bial launches video campaign for World Parkinson’s Day

Aims to challenge negative portrayals of people with the disease

Holding on to hope for Alzheimer’s advances

Despite another late-stage failure, now is not the time to give up on the disease

- PMLiVE

Online brain training game to be trialled for Parkinson’s disease

MyCognition's AquaSnap Optimize aims to tackle cognitive impairment

EU flag

EMA unveils draft guidelines for Alzheimer’s disease research

Puts plans for evaluating potential new therapies out for consultation

UCB trials wearable sensor for Parkinson’s

Its medical device combines with a mobile app to measure motor symptom patterns

- PMLiVE

Glimmer of hope for amyloid drugs in Alzheimer’s?

Expectations remain high but high efficacy rates still allusive for most firms

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links